- Home
- INSW vs BLTE Comparison
INSW vs BLTE Comparison
Compare INSW & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSW
- BLTE
- Stock Information
- Founded
- INSW 1999
- BLTE 2018
- Country
- INSW United States
- BLTE United States
- Employees
- INSW N/A
- BLTE N/A
- Industry
- INSW Semiconductors
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- INSW Technology
- BLTE Health Care
- Exchange
- INSW Nasdaq
- BLTE Nasdaq
- Market Cap
- INSW 2.3B
- BLTE 2.1B
- IPO Year
- INSW N/A
- BLTE 2022
- Fundamental
- Price
- INSW $47.08
- BLTE $75.60
- Analyst Decision
- INSW Buy
- BLTE Strong Buy
- Analyst Count
- INSW 2
- BLTE 4
- Target Price
- INSW $52.00
- BLTE $96.00
- AVG Volume (30 Days)
- INSW 524.7K
- BLTE 58.4K
- Earning Date
- INSW 11-06-2025
- BLTE 11-11-2025
- Dividend Yield
- INSW 6.94%
- BLTE N/A
- EPS Growth
- INSW N/A
- BLTE N/A
- EPS
- INSW 4.81
- BLTE N/A
- Revenue
- INSW $798,838,000.00
- BLTE N/A
- Revenue This Year
- INSW N/A
- BLTE N/A
- Revenue Next Year
- INSW $4.49
- BLTE N/A
- P/E Ratio
- INSW $9.79
- BLTE N/A
- Revenue Growth
- INSW N/A
- BLTE N/A
- 52 Week Low
- INSW $27.20
- BLTE $48.01
- 52 Week High
- INSW $54.84
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- INSW 54.66
- BLTE 65.93
- Support Level
- INSW $45.06
- BLTE $70.80
- Resistance Level
- INSW $47.71
- BLTE $74.20
- Average True Range (ATR)
- INSW 1.03
- BLTE 2.70
- MACD
- INSW -0.37
- BLTE 0.41
- Stochastic Oscillator
- INSW 47.75
- BLTE 100.00
About INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.